[VIEW] agent=Patient Safety & Quality Director | scenario_id=115 | rounds=20

--- Round 0 ---
[R0.1] Patient Safety & Quality Director (speak, private to=Biomedical Engineering Manager,Supply Chain & Procurement Director): To effectively respond to the FDA Class I recall of the IVP-500 infusion pumps, we need to assess our operational capacity for the mitigations and the scale of the affected devices. Can you provide insights on how many devices we currently have in the high-risk units, and what our readiness looks like for implementing the updated clamp protocol within the required timeline?
[R0.2] Biomedical Engineering Manager (speak, private to=Patient Safety & Quality Director): Currently, we have 410 IVP-500 infusion pumps in our inpatient campuses. Regarding the updated clamp protocol, I need to understand the urgency and clinical expectations for mitigation, as well as any immediate backup inventory we have. Could you clarify these points for us?
[R0.3] Supply Chain & Procurement Director (speak, public): We currently have 34 spare pumps available in our central depot, which can be used as immediate contingency stock. Regarding the lead time for replacement pumps, we have a standard lead time of 8 weeks. I can provide further details on the recall credit program, which is $900 per returned pump, and our current vendor discount rate of 12% on new pumps. However, I need insights on the number of devices in high-risk units and the operational effort required for implementing the updated protocols to fully assess our readiness and risks.

--- Round 1 ---
[R1.1] Patient Safety & Quality Director (speak, private to=Biomedical Engineering Manager,Supply Chain & Procurement Director): To clarify, we have 410 IVP-500 infusion pumps across our inpatient campuses, with 58 located in the ICU, which is a high-risk unit. It's crucial we implement the updated clamp protocol within 7 days to mitigate risks. I understand we have 34 spare pumps available, which will help as a contingency. Can we confirm the operational readiness to execute these mitigations and ensure our staff is trained accordingly?
[R1.2] Biomedical Engineering Manager (speak, public): To ensure we are operationally ready for the updated clamp protocol within the 7-day timeframe, I recommend we prioritize training sessions for the staff, particularly in the high-risk areas like the ICU. Additionally, we should begin scheduling the firmware patch installations on the pumps as soon as possible. This will help address the occlusion alarm delay issue and ensure patient safety while we assess the need for further replacements. Can we confirm the training schedule and any necessary resources to facilitate this?
[R1.3] Supply Chain & Procurement Director (speak, public): I appreciate the urgency and the steps outlined for the training sessions. To align our procurement efforts with the operational readiness, could you provide a timeline for when the firmware patch installations can begin? Additionally, if there are any undisclosed device-condition signals or regulatory escalations we should be aware of, please let me know. I want to ensure that our procurement strategy is fully informed and supports the immediate needs effectively.

--- Round 2 ---
[R2.1] Patient Safety & Quality Director (leave, public): 
[R2.2] Biomedical Engineering Manager (leave, public): 
[R2.3] Supply Chain & Procurement Director (leave, public): 

--- Round 3 ---
[R3.1] Patient Safety & Quality Director (leave, public): 
[R3.2] Biomedical Engineering Manager (leave, public): 
[R3.3] Supply Chain & Procurement Director (leave, public): 

--- Round 4 ---
[R4.1] Patient Safety & Quality Director (leave, public): 
[R4.2] Biomedical Engineering Manager (leave, public): 
[R4.3] Supply Chain & Procurement Director (leave, public): 

--- Round 5 ---
[R5.1] Patient Safety & Quality Director (leave, public): 
[R5.2] Biomedical Engineering Manager (leave, public): 
[R5.3] Supply Chain & Procurement Director (leave, public): 

--- Round 6 ---
[R6.1] Patient Safety & Quality Director (leave, public): 
[R6.2] Biomedical Engineering Manager (leave, public): 
[R6.3] Supply Chain & Procurement Director (leave, public): 

--- Round 7 ---
[R7.1] Patient Safety & Quality Director (leave, public): 
[R7.2] Biomedical Engineering Manager (leave, public): 
[R7.3] Supply Chain & Procurement Director (leave, public): 

--- Round 8 ---
[R8.1] Patient Safety & Quality Director (leave, public): 
[R8.2] Biomedical Engineering Manager (leave, public): 
[R8.3] Supply Chain & Procurement Director (leave, public): 

--- Round 9 ---
[R9.1] Patient Safety & Quality Director (leave, public): 
[R9.2] Biomedical Engineering Manager (leave, public): 
[R9.3] Supply Chain & Procurement Director (leave, public): 

--- Round 10 ---
[R10.1] Patient Safety & Quality Director (leave, public): 
[R10.2] Biomedical Engineering Manager (leave, public): 
[R10.3] Supply Chain & Procurement Director (leave, public): 

--- Round 11 ---
[R11.1] Patient Safety & Quality Director (leave, public): 
[R11.2] Biomedical Engineering Manager (leave, public): 
[R11.3] Supply Chain & Procurement Director (leave, public): 

--- Round 12 ---
[R12.1] Patient Safety & Quality Director (leave, public): 
[R12.2] Biomedical Engineering Manager (leave, public): 
[R12.3] Supply Chain & Procurement Director (leave, public): 

--- Round 13 ---
[R13.1] Patient Safety & Quality Director (leave, public): 
[R13.2] Biomedical Engineering Manager (leave, public): 
[R13.3] Supply Chain & Procurement Director (leave, public): 

--- Round 14 ---
[R14.1] Patient Safety & Quality Director (leave, public): 
[R14.2] Biomedical Engineering Manager (leave, public): 
[R14.3] Supply Chain & Procurement Director (leave, public): 

--- Round 15 ---
[R15.1] Patient Safety & Quality Director (leave, public): 
[R15.2] Biomedical Engineering Manager (leave, public): 
[R15.3] Supply Chain & Procurement Director (leave, public): 

--- Round 16 ---
[R16.1] Patient Safety & Quality Director (leave, public): 
[R16.2] Biomedical Engineering Manager (leave, public): 
[R16.3] Supply Chain & Procurement Director (leave, public): 

--- Round 17 ---
[R17.1] Patient Safety & Quality Director (leave, public): 
[R17.2] Biomedical Engineering Manager (leave, public): 
[R17.3] Supply Chain & Procurement Director (leave, public): 

--- Round 18 ---
[R18.1] Patient Safety & Quality Director (leave, public): 
[R18.2] Biomedical Engineering Manager (leave, public): 
[R18.3] Supply Chain & Procurement Director (leave, public): 

--- Round 19 ---
[R19.1] Patient Safety & Quality Director (leave, public): 
[R19.2] Biomedical Engineering Manager (leave, public): 
[R19.3] Supply Chain & Procurement Director (leave, public): 

